Shots:

• The conditional approval is based on results from a P-II trial in China evaluating the safety & efficacy of Brukinsa in patients with WM who have received at least one prior therapy
• Results: @median follow-up time of 14.9mos.- MRR (72.1%) as assessed by IRC & AEs profile was generally consistent with previous findings
• Brukinsa is a BTK inhibitor & marks the third approval for the treatment of B-cell malignancies in China- currently being evaluated in multiple clinical studies globally as a monothx. or in combination with other therapies targeting B cell malignancies

  | Ref: Business Wire | Image: BioSpace